Revisiting study design and methodology for pathogen reduced platelet transfusions: a round table discussion

Area of Science:

• Transfusion Medicine
• Blood Safety Technologies
• Hematology

Background:

• Pathogen inactivation/reduction technologies enhance microbial safety of platelet components.
• Current clinical trials to assess efficacy are lengthy, costly, and require large patient cohorts.
• There is a need for more efficient methods to evaluate these vital blood products.

Purpose of the Study:

• To explore novel approaches for evaluating the clinical efficacy of pathogen-reduced platelets.
• To discuss challenges associated with traditional clinical trial designs for pathogen-reduced platelet assessment.
• To identify potential surrogate markers and alternative trial methodologies.

Main Methods:

• Expert presentations on new evaluation strategies.
• Roundtable discussion among specialists in transfusion medicine and blood safety.
• Exploration of laboratory measures as surrogates for clinical outcomes.
• Consideration of alternative clinical trial designs, including cluster trials, stepped wedge designs, and Phase 4 studies.

Main Results:

• The limitations of traditional clinical trials for pathogen-reduced platelets were highlighted.
• The potential utility of laboratory measures (e.g., post-transfusion platelet count) as surrogates was discussed.
• Alternative trial designs and the need for standardized safety endpoints were considered crucial for future evaluations.

Conclusions:

• Innovative strategies are required to streamline the evaluation of pathogen-reduced platelet efficacy and safety.
• Integrating laboratory measures and alternative trial designs may offer more efficient assessment pathways.
• Standardized safety endpoints are essential for reliable evaluation of pathogen-reduced platelet components.